Curevac receives positive validity decision from european patent office in litigation against biontech se

European patent office largely dismisses opposition filed by biontech se in april 2023 challenging validity of ep 3 708 668 b1 and maintains the patent in amended form a hearing on infringement of ep 3 708 668 b1 is scheduled for july 1, 2025, before the regional court dÜsseldorf confirming validity of patent in its amended form marks major milestone in broader patent litigation in germany, recognizing curevac's pioneering mrna innovation tÜbingen, germany and boston, ma / access newswire / march 27, 2025 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that the european patent office (epo) has confirmed the validity of curevac's european patent ep 3 708 668 b1 subject to amendments to specify the scope of protection.
CVAC Ratings Summary
CVAC Quant Ranking